Innovative Diagnostic System Strand Diagnostics' know error system offers a unique DNA-based verification process for biopsy samples, providing an opportunity to collaborate with healthcare providers seeking to improve diagnostic accuracy and reduce misdiagnosis risks.

Growing Market Presence Having processed over 300,000 patient samples and launched targeted solutions for breast and prostate biopsies, the company is well-positioned to expand its reach into other diagnostic markets and attract healthcare facilities prioritizing precision medicine.

Strong Funding Support With a recent $30 million in Series A funding and a revenue range of $1M to $10M, Strand Diagnostics is investing in scaling its operations and marketing efforts, presenting potential sales opportunities in healthcare institutions and labs seeking innovative DNA verification tools.

Regulatory and Accreditation Credentials Maintaining FBI accreditation since 2005 and CLIA certification since 2008, the company emphasizes compliance and quality standards, making it a trusted partner for medical laboratories and public safety agencies interested in reliable forensic and diagnostic solutions.

Technology Stack & Digital Presence Utilizing platforms like WordPress, MySQL, and Microsoft 365, Strand Diagnostics maintains a modern digital footprint, indicating openness to integrating new technological solutions and digital marketing channels to support sales expansion efforts.